Diana Vakante Jankovic, MD
Family Medicine · Orchard Park, NYNPI 1457330623
Payments from drug & device makers
Across 181 payments — averaging $20.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$480
- Novo Nordisk$384
- Amgen$377
- Lilly USA, LLC$368
- AstraZeneca$264
- Pfizer$182
- plus $2K from 31 others
What the payments were for
- Consulting fees$44512%
- Food & beverage$3,19187%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 15 | $480 |
| Novo Nordisk | 23 | $384 |
| Amgen(2 entities) | 14 | $377 |
| Lilly USA, LLC | 22 | $368 |
| AstraZeneca | 16 | $264 |
| Pfizer | 11 | $182 |
| Merck | 9 | $166 |
| Boehringer Ingelheim | 7 | $136 |
| AbbVie | 5 | $125 |
| Johnson & Johnson | 7 | $113 |
| Amarin Pharma, Inc. | 7 | $110 |
| Exact Sciences | 4 | $86 |
| Sanofi-aventis U.S. LLC | 4 | $73 |
| Phathom Pharmaceuticals, Inc. | 2 | $64 |
| Esperion Therapeutics, Inc. | 4 | $57 |
| Eisai Inc. | 2 | $52 |
| Bayer | 2 | $51 |
| Abbott | 2 | $49 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| Mannkind Corporation | 2 | $42 |
| Corium, LLC | 2 | $40 |
| Dexcom, Inc. | 2 | $40 |
| Novartis | 2 | $39 |
| Globus Medical | 1 | $39 |
| Amneal Pharmaceuticals LLC | 2 | $35 |
| Edwards Lifesciences | 1 | $34 |
| Corcept Therapeutics | 1 | $26 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Radius Health, Inc. | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Seqirus USA Inc | 1 | $18 |
| Cipher Pharmaceuticals US LLC | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $17 |
| Cequr Corporation | 1 | $13 |
| Lifescan, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,651 in reported general payments places this provider in the 85th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 124 | $159,285 |
| JardianceEmpagliflozin | 130 | $147,401 |
| OzempicSemaglutide | 80 | $118,768 |
| FarxigaDapagliflozin Propanediol | 92 | $95,156 |
| TrulicityDulaglutide | 44 | $56,137 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $28,058 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $23,615 |
| RybelsusSemaglutide | 15 | $22,821 |
| EliquisApixaban | 18 | $20,373 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $18,189 |
| ProliaDenosumab | 11 | $17,945 |
| Spiriva HandihalerTiotropium Bromide | 24 | $14,808 |
| Rosuvastatin Calcium | 749 | $13,347 |
| VascepaIcosapent Ethyl | 14 | $11,303 |
| Levothyroxine Sodium | 647 | $10,289 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $368 | $215,422168 claims |
| Boehringer IngelheimJardiance | $136 | $147,401130 claims |
| Novo NordiskOzempic, Rybelsus | $384 | $141,58995 claims |
| AstraZenecaFarxiga | $264 | $95,15692 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $480 | $41,80456 claims |
| PfizerEliquis | $182 | $20,37318 claims |
| AmgenProlia | $377 | $17,94511 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $35 | $10,289647 claims |
| Johnson & JohnsonXarelto | $113 | $10,08012 claims |
| Esperion Therapeutics, Inc.Nexletol | $57 | $7,13413 claims |
| AbbVieSynthroid | $125 | $2,89971 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,321 family medicine providers in New York.
Other family medicine in Orchard Park
- Richard RuhOrchard Park$769K
- Thomas DilamarterOrchard Park$42K
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.